@article {7765,
	title = {Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma},
	journal = {Haematologica},
	volume = {95},
	year = {2010},
	note = {Cited By :88Export Date: 21 February 2017},
	month = {2010},
	pages = {1738 - 1744},
	abstract = {Background This retrospective pooled analysis of two phase III trials (MM-009/MM-010) compared clinical outcomes of patients who achieved a complete response or very good partial response to treatment with lenalidomide plus dexamethasone with the outcomes of those who only achieved a partial response. Design and Methods Patients (n=353) received lenalidomide (25 mg/day for 21 days of each 28-day cycle) plus dexamethasone (40 mg on days 1-4, 9-12, and 17-20 for four cycles, and only on days 1-4 after the first four cycles). Time to response, duration of response, time-to-progression, overall survival, and adverse events were investigated for patients who had a complete or very good partial response and compared with those of patients who had a partial response. Results At the time of unblinding, 32\% of patients had achieved a complete or very good partial response and 28\% had a partial response. Half (50.5\%) of the patients who had a partial response as their initial response achieved a complete or very good partial response with further treatment. The probability of achieving a complete or very good partial response with continued lenalidomide treatment decreased with delayed achievement of a partial response (by cycle 4 versus later); however, it remained clinically significant. With an extended follow-up of 48 months, the median response duration, time-to-progression, and overall survival were longer in patients with a complete or very good partial response than in those with a partial response (24.0 versus 8.3 months, P<0.001; 27.7 versus 12.0 months, P<0.001; not reached versus 44.2 months, P=0.021, respectively). The benefit of a complete or very good partial response was independent of when it was achieved. Conclusions Continuing treatment with lenalidomide plus dexamethasone to achieve best response, in the absence of disease progression and toxicity, provided deeper remissions and greater clinical benefit over time for patients in this study. {\textcopyright} 2010 Ferrata Storti Foundation.},
	keywords = {Clinical benefit, Dexamethasone, Efficacy, Lenalidomide, multiple myeloma, Response},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-77957774888\&doi=10.3324\%2fhaematol.2009.015917\&partnerID=40\&md5=8ea25cb20d72d3b4d519f94e842b0fa6},
	author = {Harousseau, J.-L. and Dimopoulos, M.A. and Wang, M. and Corso, A. and Chen, C. and Attal, M. and Spencer, A. and Yu, Z. and Olesnyckyj, M. and Zeldis, J.B. and Knight, R.D. and Weber, D.M.}
}
